Drug details
Capecitabine (Xeloda) Tablets (capecitabine tablets)
type of
Capecitabine Tablets are a nucleoside metabolic inhibitor with antineoplastic activity indicated for adjuvant colon cancer (patients with Dukes' C colon cancer); metastatic colorectal cancer (first-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred); and metastatic breast cancer (in combination with docetaxel after failure of prior anthracycline-containing therapy, and as monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen). Capecitabine is available in generic form.
This drug may have the following side effects:
- nausea,
- headache,
- dizziness,
- vomiting,
- indigestion,
- weakness,
- constipation,
- loss of appetite,
- fever,
- rash,
- fatigue,
- diarrhea (may be severe),
- hand-and-foot syndrome,
- abdominal pain,
- high levels of bilirubin in the blood (hyperbilirubinemia),
- swelling of the lips and tongue,
- hair loss,
- skin redness,
- lethargy,
- changes in taste,
- pinkeye (conjunctivitis),
- low levels of white blood cells (neutropenia), and
- nosebleed.
The following drugs are related to Capecitabine (Xeloda) Tablets, either as a replacement or used together:
- Xeloda (capecitabine)
- Totect (dexrazoxane for injection, intravenous infusion only)
- Docefrez (docetaxel)
- Faslodex (fulvestrant)
- Fentora (fentanyl buccal tablet)
- Ibrance (palbociclib capsules for oral administration)
- Perjeta (pertuzumab)